Skip to content
About
Close About
Open About
Mission
Guiding Principles
Collaborations & Partnerships
Mission
Guiding Principles
Collaborations & Partnerships
Solid Team
Management
Board of Directors
Duchenne Scientific Advisory Board
Founders
Solid Team
Management
Board of Directors
Duchenne Scientific Advisory Board
Founders
Working at Solid
Culture
Benefits
Open Positions
Working at Solid
Culture
Benefits
Open Positions
Our Science
Close Our Science
Open Our Science
Pipeline & Programs
Pipeline
Scientific Publications & Presentations
Pipeline & Programs
Pipeline
Scientific Publications & Presentations
Infrastructure
Manufacturing
Infrastructure
Manufacturing
Patient & Caregiver Resources
Close Patient & Caregiver Resources
Open Patient & Caregiver Resources
Duchenne Muscular Dystrophy
What is Duchenne?
Why Gene Transfer?
Duchenne Patient Stories
Duchenne Muscular Dystrophy
What is Duchenne?
Why Gene Transfer?
Duchenne Patient Stories
Friedreich’s Ataxia Resources
Friedreich’s Ataxia
What is Frataxin?
For Patients
Friedreich’s Ataxia Resources
Friedreich’s Ataxia
What is Frataxin?
For Patients
Strength in Community
Engaging the Community
Charity Partners
Insights & News
Strength in Community
Engaging the Community
Charity Partners
Insights & News
Resources & Policies
Expanded Access Policy
Clinical Trials
Resources & Policies
Expanded Access Policy
Clinical Trials
Investors & Media
Close Investors & Media
Open Investors & Media
Overview & News
Overview
Press Releases
Presentations
Events
Governance & Financials
Governance Documents
Committee Charters
Committee Composition
SEC Filings
Stock Information
Stock Quote Chart
Historical Price Lookup
Analyst Coverage
Investor Resources
Investor FAQs
Contact Solid Biosciences
Email Alerts
A Next Generation Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy
